HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS
申请人:AstraZeneca AB
公开号:US20220127281A1
公开(公告)日:2022-04-28
The specification relates to compounds of Formula (I):
and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.